Compare BlackRock TCP Capital Corp (TCPC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BlackRock TCP Capital Corp vs 10X Genomics Inc — how do they compare? BlackRock TCP Capital Corp trades at $4.03 (market cap $337.71M), while 10X Genomics Inc trades at $81.61 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 29.8× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 18.88% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold BlackRock TCP Capital Corp for 88 Days and 10X Genomics Inc for 91 Days on average.
| TCPC | TXG | |
|---|---|---|
Market Cap | $337.71M | $10.07B |
Volume | 436,109 | 5,657,286 |
Sector | Financials | Health |
52-Week High | $6.20 | $97.74 |
52-Week Low | $3.13 | $11.48 |
Typical Hold Time | 88 Days | 91 Days |
Enterprise Value | $1.09B | $9.59B |
Dividend Yield | 18.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TCPC trades at $4.035, up 2.41% today, with a bullish technical signal supported by moving averages. The company reported mixed earnings with Q2 2026 beating estimates but faces negative revenue and net income trends. Recent portfolio sales and strategic reviews aim to reduce leverage and enhance shareholder value. Analyst consensus shows 30.77% buy ratings with no sell recommendations.
Outlook remains cautious due to declining revenue and negative profitability metrics, though strategic moves may stabilize operations. Key risks include ongoing financial losses and competitive pressures in the BDC sector. Investment opportunity hinges on successful execution of portfolio optimization and debt reduction initiatives.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
